首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology
【24h】

Isotypic analysis of antibodies against activated Factor VII in patients with Factor VII deficiency using the x-MAP technology

机译:使用x-MAP技术对因子VII缺乏症患者的激活的VII因子抗体进行同型分析

获取原文
获取原文并翻译 | 示例
           

摘要

While the immune response to hemophilic factors in hemophilia has been widely studied, little is known about the development of anti-Factor VII (FVII) antibodies in FVII deficiency. We developed a robust technique based on the x-MAP technology to detect the presence of antibodies against FVII and characterize their isotype and validated this method using blood samples from 100 patients with FVII deficiency (median FVII clotting activity [FVII:C]: 6%) and 95 healthy controls. Anti-FVII antibodies were detected in patients but also in some controls, although the concentration of total immunoglobulin G (IgGt) and IgG(1) and IgG(4) subclasses was significantly different between groups. The IgG1 subclass concentrations remained significantly different also when only untreated patients were compared with controls. This difference could partially be related to the F7 genotype, particularly in patients harboring the p.Arg139Gln mutation. This x-MAP-based method might be useful for assessing the immunogenicity of novel FVII compounds and of activated FVII (FVIIa) concentrates. Further prospective studies are needed to better understand the clinical relevance of these antibodies in the management of patients with FVII deficiency. (C) 2016 Elsevier Ltd. All rights reserved.
机译:虽然已经对血友病中对血友病因子的免疫应答进行了广泛研究,但对于缺乏FVII的抗因子VII(FVII)抗体的开发知之甚少。我们开发了一种基于x-MAP技术的可靠技术来检测抗FVII抗体的存在并鉴定其同种型,并使用100例FVII缺乏症患者的血液样本对该方法进行了验证(中位FVII凝血活性[FVII:C]:6% )和95个健康对照。尽管两组之间总免疫球蛋白G(IgGt)和IgG(1)和IgG(4)亚类的浓度显着不同,但在患者以及某些对照中均检测到抗FVII抗体。当仅将未经治疗的患者与对照组进行比较时,IgG1亚类的浓度仍显着不同。这种差异可能部分与F7基因型有关,特别是在携带p.Arg139Gln突变的患者中。这种基于x-MAP的方法可能有助于评估新型FVII化合物和活化FVII(FVIIa)浓缩物的免疫原性。需要进行进一步的前瞻性研究,以更好地了解这些抗体在FVII缺乏症患者管理中的临床意义。 (C)2016 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号